NAMPT and Other metabolic disease: Enhanced circulating levels of visfatin have been reported in patients affected by metabolic disorders, such as diabetes mellitus, obesity or the metabolic syndrome [6,7], which might be related to the development of cardiovascular complications linked to these diseases.